Secondary prevention of hemorrhagic complications and pharmacokinetics of factor VIII in children with severe hemophilia A

Cover Page

Cite item

Full Text

Abstract

Individual selection of dose and calculation of ratio for prevention of the introduction of the concentrate of coagulation factor VIII 23 patients with severe hemophilia A carried out the pharmacokinetic study. The half-life of exogenous factor VIII is 12 hours, registered in 12 (52%) patients, 7 boys (30%) - the half-life of factor VIII was 18 hours, in 4 (18%) children - 11 hours. Individual pharmacokinetic calculations allowed to carry out secondary prevention of spontaneous bleeding with multiplicity systematic introduction of a concentrate of coagulation factor VIII in 72, 96, or 48 hours, respectively, without bleeding complications. The combined change in parameters such as higher clearance (Cl) to 5,3 ml х kg-1 х hour-1, volume of distribution (Vd) to 79.0 ml х kg-1 with the decline in the normalized measure of the area under the curve (AUCnorm) to 14.7 ml-1 х h х kg and the recovery index (Recovery in vivo) to 1.27 % / ME х kg-1 and half-life (T/) to 11.0 hours, characterizes a type of inhibitory response to the introduction of the concentrate of coagulation factor VIII.

About the authors

Vyacheslav V. Dmitriev

Republican Scientific Centre of Pediatric Oncology, Hematology and Immunology, Ministry of Health

Author for correspondence.
Email: dmitrievhaematol@mail.ru
Russian Federation

Ludmila I. Volkova

Belarusian Medical Academy of Post-Graduate Education Ministry of Health

Email: luidmila_volkova@mail.ru
Russian Federation

Evgeniy V. Dmitriev

Republican Scientific Centre of Pediatric Oncology, Hematology and Immunology, Ministry of Health

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Dmitriev V.V., Volkova L.I., Dmitriev E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.